The data presented herein indicate that PRG4 has the potential to enhance the anti-tumor efficacy of regorafenib in the treatment of hepatocellular carcinoma (HCC), without necessitating dose escalation and thereby mitigating the risk of associated side effects. Here, PRG4 is linked to hepatocellular carcinoma.